 Protagonist Therapeutics PTGX stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace. 